<DOC>
	<DOCNO>NCT01798745</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( ie , body affect drug ) pharmacodynamics ( ie , drug affect body ) JNJ-54452840 participant heart failure anti-beta1-adrenergic receptor autoantibody . The safety tolerability JNJ-54452840 also assess .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Pharmacodynamics JNJ-54452840 Participants With Heart Failure Anti-beta1-adrenergic Receptor Autoantibodies</brief_title>
	<detailed_description>This study randomize ( study treatment assign chance ) , double-blind ( neither investigator participant know treatment receive ) , placebo-controlled ( one study treatment inactive ) . This study conduct participant reduce systolic function heart failure ( reduced amount blood pump around body compare normal heart ) elevate level anti-beta1-adrenergic receptor autoantibody ( antibody may involve development , progression , worsen heart failure ) . The study conduct 2 part ; participant receive single dos JNJ-54452840 Part 1 multiple dos Part 2 . Each part study consist 3 phase ; screen phase , double-blind treatment phase , follow-up phase . There 2 cohort ( group ) participant Part 1 study . In Part 1 ( Cohort A ) , participant randomly assign 1 4 treatment group : single intravenous ( medication inject vein ) dose 20 mg JNJ-54452840 ; single intravenous dose 80 mg JNJ-54452840 ; single intravenous dose 160 mg JNJ-54452840 ; match placebo ( inactive medication ) . In Part 1 ( Cohort B ) , participant randomly assign 1 2 treatment group ; single intravenous dose less equal 240 mg JNJ-54452840 ( determine Data Review Committee review Cohort A data ) matching placebo . There 4 cohort participant Part 2 study ; dose JNJ-54452840 used cohort , initiation cohort , sequence decide Data Review Committee . In Part 2 ( Cohort C ) , participant randomly assign 1 2 treatment group : JNJ-54452840 matching placebo give intravenously daily 3 day . In Part 2 ( Cohort D ) , participant randomly assign 1 2 treatment group : JNJ-54452840 matching placebo give intravenously daily 5 day . In Part 2 ( Cohort E ) , participant randomly assign 1 2 treatment group : JNJ-54452840 matching placebo give intravenously weekly Days 1 , 8 , 15 , 22 . In Part 2 ( Cohort F ) , participant randomly assign 1 treatment group involve regimen ( ) explore Cohorts C , D , E. Single dose JNJ-54452840 great 240 mg Cohort . The active placebo randomization ratio cohort follow Cohort A ( ie , Cohorts B , C , D , E , F ) determine Data Review Committee . Participants come study center time receive study medication remain center least two hour follow injection . Blood sample draw time point screen period treatment period participant Part 1 Part 2 study . Participants return study center double-blind treatment phase Day 29 follow-up visit Days 57 85 . Participants Part 1 Part 2 involve study approximately 112 day . Participant safety monitor . The study drug , JNJ-54452480 investigate treatment heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<criteria>Must document medical history symptomatic ( ie , show symptom ) reduce ejection fraction ( measurement percentage blood leave heart time contract ) heart failure due either ischemic etiology ( decrease blood supply heart ) nonischemic dilate cardiomyopathy ( heart weaken enlarge ) least 4 month prior screen visit Must heart failure classify New York Heart Association classification system class I IIIa Must leave ventricular ejection fraction ( measurement percentage blood leave heart time contract ) &lt; = 45 % Must blood level antibeta1adrenergic receptor autoantibody ( antibody involve develop heart failure ) reference range Must receiving guidelinedirected medical therapy heart failure least 4 month prior screen , addition , receive stable individually optimized drug dos least 2 month prior screen . History , current active illness , opinion investigator , would make participation best interest ( eg , compromise wellbeing ) patient could interfere study assessment Left ventricular enddiastolic diameter index ( measure heart 's performance ) &lt; = 32 mm/m2 Nterminal probrain natriuretic peptide level ( biologic molecule show predict cardiac event ) &lt; = 200 pg/mL participant normal sinus rhythm &lt; = 800 pg/mL participant atrial fibrillation Chronic treatment immunosuppressive drug ( except &lt; = 5 mg/day prednisoneequivalent dose ) Known allergy peptides protein , albumin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>JNJ-54452840</keyword>
	<keyword>Anti-beta-1 adrenergic receptor auto antibody</keyword>
	<keyword>Beta-1 adrenergic receptor</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Auto antibody</keyword>
	<keyword>Systolic function</keyword>
</DOC>